Epigenetics in radiotherapy: Where are we heading?

Radiotherapy and Oncology

Volumn 111, Issue 2, 2014, Pages 168-177

  Smits, Kim M ^a   Melotte, Veerle ^a   Niessen, Hanneke E C ^a   Dubois, Ludwig ^a   Oberije, Cary ^a   Troost, Esther G C ^a   Starmans, Maud H W ^a,b   Boutros, Paul C ^b,c,d   Vooijs, Marc ^a   Van Engeland, Manon ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

DNA methylation; Epigenetic biomarkers; Histone modifications; Hypoxia; Radiotherapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; BIOLOGICAL MARKER; BRCA1 PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE INHIBITOR; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E; INITIATION FACTOR 4F; MOLECULAR MARKER; NUCLEOSIDE ANALOG; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; S ADENOSYLMETHIONINE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; RADIOSENSITIZING AGENT; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BYSTANDER EFFECT; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; CLINICAL DECISION MAKING; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; EMBRYONIC STEM CELL; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; EPSTEIN BARR VIRUS; GASTRIC CANCER CELL LINE; GENE EXPRESSION; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTONE MODIFICATION; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MOUTH SQUAMOUS CELL CARCINOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UBIQUITINATION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902549532     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.05.001     Document Type: Review

References (172)

1. M. Merrifield, and O. Kovalchuk Epigenetics in radiation biology: a new research frontier Front Genet 4 2013 40
2. G.L. Gravina, C. Festuccia, and F. Marampon et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation Mol Cancer 9 2010 305
3. A. Yaromina, M. Krause, and M. Baumann Individualization of cancer treatment from radiotherapy perspective Mol Oncol 6 2012 211 221
4. O. Popanda, J.U. Marquardt, J. Chang-Claude, and P. Schmezer Genetic variation in normal tissue toxicity induced by ionizing radiation Mutat Res 667 2009 58 69
5. K. Haustermans, A. Debucquoy, and M. Lambrecht The ESTRO Breur Lecture 2010: toward a tailored patient approach in rectal cancer Radiother Oncol 100 2011 15 21
6. A.C. Begg Predicting response to radiotherapy: evolutions and revolutions Int J Radiat Biol 85 2009 825 836
7. C. Dehing-Oberije, D. De Ruysscher, and H. van der Weide et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy Int J Radiat Oncol Biol Phys 70 2008 1039 1044
8. C. Dehing-Oberije, S. Yu, and D. De Ruysscher et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 74 2009 355 362
9. C. Dehing-Oberije, D. De Ruysscher, A. van Baardwijk, S. Yu, B. Rao, and P. Lambin The importance of patient characteristics for the prediction of radiation-induced lung toxicity Radiother Oncol 91 2009 421 426
10. L.B. Marks, S.M. Bentzen, and J.O. Deasy et al. Radiation dose-volume effects in the lung Int J Radiat Oncol Biol Phys 76 2010 S70 S76
11. C. Dehing-Oberije, D. De Ruysscher, and S. Petit et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients Radiother Oncol 97 2010 455 461
12. R.G. van Stiphout, G. Lammering, and J. Buijsen et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging Radiother Oncol 98 2011 126 133
13. V. Valentini, R.G. van Stiphout, and G. Lammering et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials J Clin Oncol 29 2011 3163 3172
14. A.G. Egelmeer, E.R. Velazquez, and J.M. de Jong et al. Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients Radiother Oncol 100 2011 108 115
15. M.E. Christianen, C. Schilstra, and I. Beetz et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study Radiother Oncol 105 2012 107 114
16. B.L. Ramaekers, J.P. Grutters, M. Pijls-Johannesma, P. Lambin, M.A. Joore, and J.A. Langendijk Protons in head-and-neck cancer: bridging the gap of evidence Int J Radiat Oncol Biol Phys 85 2013 1282 1288
17. B.L. Ramaekers, M.A. Joore, and J.P. Grutters et al. The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy Oral Oncol 47 2011 768 774
18. B.L. Ramaekers, M. Pijls-Johannesma, and M.A. Joore et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons Cancer Treat Rev 37 2011 185 201
19. H.P. van der Laan, T.A. van de Water, and H.E. van Herpt et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study Acta Oncol 52 2013 561 569
20. H.P. Rodemann, and B.G. Wouters Molecular and translational radiation biology/oncology: what's up? Radiother Oncol 99 2011 257 261
21. M. van Engeland, S. Derks, K.M. Smits, G.A. Meijer, and J.G. Herman Colorectal cancer epigenetics: complex simplicity J Clin Oncol 29 2011 1382 1391
22. A.P. Feinberg, and B. Tycko The history of cancer epigenetics Nat Rev Cancer 4 2004 143 153
23. P.A. Jones, and P.W. Laird Cancer epigenetics comes of age Nat Genet 21 1999 163 167
24. A.P. Wolffe, and M.A. Matzke Epigenetics: regulation through repression Science 286 1999 481 486
25. S. Baylin, and T.H. Bestor Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1 2002 299 305
26. P.W. Laird Cancer epigenetics Hum Mol Genet 14 2005 R65 76
27. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
28. S.B. Baylin, M. Esteller, M.R. Rountree, K.E. Bachman, K. Schuebel, and J.G. Herman Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer Hum Mol Genet 10 2001 687 692
29. M. Esteller, M.F. Fraga, and M.F. Paz et al. Cancer epigenetics and methylation Science 297 2002 1807 1808 discussion 1807-1808
30. P.A. Jones Functions of DNA methylation: islands, start sites, gene bodies and beyond Nat Rev Genet 13 2012 484 492
31. J.U. Guo, Y. Su, C. Zhong, G.L. Ming, and H. Song Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond Cell Cycle 10 2011 2662 2668
32. M.R. Branco, G. Ficz, and W. Reik Uncovering the role of 5-hydroxymethylcytosine in the epigenome Nat Rev Genet 13 2012 7 13
33. M.A. Dawson, and T. Kouzarides Cancer epigenetics: from mechanism to therapy Cell 150 2012 12 27
34. J.S. You, and P.A. Jones Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22 2012 9 20
35. R. Cortese, A. Kwan, and E. Lalonde et al. Epigenetic markers of prostate cancer in plasma circulating DNA Hum Mol Genet 21 2012 3619 3631
36. J. Sandoval, and M. Esteller Cancer epigenomics: beyond genomics Curr Opin Genet Dev 22 2012 50 55
37. M.F. Fraga, E. Ballestar, and A. Villar-Garea et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat Genet 37 2005 391 400
38. D.B. Seligson, S. Horvath, and T. Shi et al. Global histone modification patterns predict risk of prostate cancer recurrence Nature 435 2005 1262 1266
39. F. Barlesi, G. Giaccone, and M.I. Gallegos-Ruiz et al. Global histone modifications predict prognosis of resected non small-cell lung cancer J Clin Oncol 25 2007 4358 4364
40. F. Barbisan, R. Mazzucchelli, and A. Santinelli et al. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential Int J Immunopathol Pharmacol 21 2008 615 623
41. D.B. Seligson, S. Horvath, and M.A. McBrian et al. Global levels of histone modifications predict prognosis in different cancers Am J Pathol 174 2009 1619 1628
42. S.E. Elsheikh, A.R. Green, and E.A. Rakha et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome Cancer Res 69 2009 3802 3809
43. R. Garcia-Baquero, P. Puerta, and M. Beltran et al. Methylation of a novel panel of tumor suppressor genes in urine moves forward non-invasive diagnosis and prognosis in bladder cancer: a two center prospective study J Urol 190 2 2013 723 730
44. L. Van De Voorde, R. Speeckaert, and D. Van Gestel et al. DNA methylation-based biomarkers in serum of patients with breast cancer Mutat Res 751 2012 304 325
45. S.C. Glockner, M. Dhir, and J.M. Yi et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer Cancer Res 69 2009 4691 4699
46. K.P. Suijkerbuijk, E. van der Wall, M. van Vooijs, and P.J. Diest Molecular analysis of nipple fluid for breast cancer screening Pathobiology 75 2008 149 152
47. A.S. Berghoff, and M. Preusser Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients - yes, but how? Clin Neuropathol 31 2012 405 408
48. M. Esteller, J. Garcia-Foncillas, and E. Andion et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 2000 1350 1354
49. M.E. Hegi, A.C. Diserens, and T. Gorlia et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
50. M. Esteller, P.G. Corn, J.M. Urena, E. Gabrielson, S.B. Baylin, and J.G. Herman Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia Cancer Res 58 1998 4515 4518
51. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis Radiother Oncol 100 2011 22 32
52. D. Thorwarth, and M. Alber Implementation of hypoxia imaging into treatment planning and delivery Radiother Oncol 97 2010 172 175
53. M.H. Starmans, K.C. Chu, and S. Haider et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer Radiother Oncol 102 2012 436 443
54. R. Seigneuric, M.H. Starmans, and G. Fung et al. Impact of supervised gene signatures of early hypoxia on patient survival Radiother Oncol 83 2007 374 382
55. B.J. Moeller, R.A. Richardson, and M.W. Dewhirst Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment Cancer Metasta Rev 26 2007 241 248
56. M.R. Horsman, B.G. Wouters, M.C. Joiner, and J. Overgaard Basic clinical radiobiology M.C. Joiner, A. van der Kogel, The oxygen effect and fractionated radiotherapy 2009 Hodder Arnold London 207 216
57. J. Overgaard Hypoxic radiosensitization: adored and ignored J Clin Oncol 25 2007 4066 4074
58. M. Hockel, and P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
59. B.G. Wouters, and M. Koritzinsky Hypoxia signalling through mTOR and the unfolded protein response in cancer Nat Rev Cancer 8 2008 851 864
60. C. Koumenis, and B.G. Wouters "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways Mol Cancer Res 4 2006 423 436
61. K.M. Rouschop, L.J. Dubois, and T.G. Keulers et al. PERK/eIF2alpha signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS Proc Natl Acad Sci U S A 110 2013 4622 4627
62. K.M. Rouschop, L. Dubois, and M.B. Schaaf et al. Deregulation of cap-dependent mRNA translation increases tumour radiosensitivity through reduction of the hypoxic fraction Radiother Oncol 99 2011 385 391
63. K.M. Smits, A.H. Cleven, and M.P. Weijenberg et al. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response Pharmacogenomics 9 2008 1903 1916
64. M.X. Draht, R.R. Riedl, and H. Niessen et al. Promoter CpG island methylation markers in colorectal cancer: the road ahead Epigenomics 4 2012 179 194
65. M.E. Hegi, L. Liu, and J.G. Herman et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26 2008 4189 4199
66. I.J. van Vlodrop, M.M. Baldewijns, and K.M. Smits et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma Am J Pathol 176 2010 575 584
67. J.M. Yi, M. Dhir, and L. Van Neste et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer Clin Cancer Res 17 2011 1535 1545
68. F. Roossink, S. de Jong, G.B. Wisman, A.G. van der Zee, and E. Schuuring DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art Cell Oncol (Dordr) 35 2012 231 241
69. C.L. Chan, Z. Wu, A. Eastman, and E. Bresnick Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells Cancer Res 52 1992 1804 1809
70. R.A. Olson, P.K. Brastianos, and D.A. Palma Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis J Neurooncol 105 2011 325 335
71. A.L. Rivera, C.E. Pelloski, and M.R. Gilbert et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 2010 116 121
72. M. Niyazi, O. Schnell, and B. Suchorska et al. FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status Radiother Oncol 104 2012 78 82
73. G. Narayan, H. Arias-Pulido, and S. Koul et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome Mol Cancer 2 2003 24
74. S.I. Bae, H.S. Lee, S.H. Kim, and W.H. Kim Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers Br J Cancer 86 2002 1888 1892
75. M. Esteller, G. Gaidano, and S.N. Goodman et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma J Natl Cancer Inst 94 2002 26 32
76. S. Baumann, G. Keller, and F. Puhringer et al. The prognostic impact of O6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma Int J Cancer 119 2006 264 268
77. A. Cayre, F. Penault-Llorca, and M. De Latour et al. O(6)-methylguanine- DNA methyl transferase gene expression and prognosis in breast carcinoma Int J Oncol 21 2002 1125 1131
78. K. Hashimoto, Y. Narita, and Y. Matsushita et al. Methylation status of O6-methylguanine-DNA-methyl transferase promoter region in non-small-cell lung cancer patients with brain metastasis Clin Transl Oncol 14 2012 31 35
79. A.S. Berghoff, H. Stefanits, H. Heinzl, and M. Preusser Clinical neuropathology practice news 4-2012: levels of evidence for brain tumor biomarkers Clin Neuropathol 31 2012 206 209
80. M.F. Lavin Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update Radiother Oncol 47 1998 113 123
81. M. Lobrich, and P.A. Jeggo The two edges of the ATM sword: co-operation between repair and checkpoint functions Radiother Oncol 76 2005 112 118
82. W.J. Kim, Q.N. Vo, M. Shrivastav, T.A. Lataxes, and K.D. Brown Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line Oncogene 21 2002 3864 3871
83. E.H. Kim, A.K. Park, S.M. Dong, J.H. Ahn, and W.Y. Park Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines Oncogene 29 2010 4725 4731
84. K. Roy, L. Wang, G.M. Makrigiorgos, and B.D. Price Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity Biochem Biophys Res Commun 344 2006 821 826
85. G.A. Tanteles, R.J. Murray, and J. Mills et al. Variation in telangiectasia predisposing genes is associated with overall radiation toxicity Int J Radiat Oncol Biol Phys 84 2012 1031 1036
86. J.C. Brandes, H. Carraway, and J.G. Herman Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter Oncogene 26 2007 6229 6237
87. J.P. Hamilton, F. Sato, and B.D. Greenwald et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer Clin Gastroenterol Hepatol 4 2006 701 708
88. C. Sakakura, K. Miyagawa, and K.I. Fukuda et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis Oncogene 26 2007 5927 5938
89. S.S. Liu, R.C. Leung, and K.Y. Chan et al. P73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy Clin Cancer Res 10 2004 3309 3316
90. H. De Schutter, H. Geeraerts, E. Verbeken, and S. Nuyts Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only Oncol Rep 21 2009 507 513
91. B. Hofstetter, A. Niemierko, and C. Forrer et al. Impact of genomic methylation on radiation sensitivity of colorectal carcinoma Int J Radiat Oncol Biol Phys 76 2010 1512 1519
92. P. Zhang, A. Singh, and S. Yegnasubramanian et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth Mol Cancer Ther 9 2010 336 346
93. L. Luzhna, and O. Kovalchuk Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis Biochem Biophys Res Commun 392 2010 113 117
94. K.H. Huang, S.F. Huang, I.H. Chen, C.T. Liao, H.M. Wang, and L.L. Hsieh Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma Clin Cancer Res 15 2009 4174 4180
95. A.K. Gupta, V.J. Bakanauskas, and G.J. Cerniglia et al. The Ras radiation resistance pathway Cancer Res 61 2001 4278 4282
96. A.K. Gupta, G.J. Cerniglia, and R. Mick et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002 Int J Radiat Oncol Biol Phys 56 2003 846 853
97. J.A. Watson, C.J. Watson, A. McCann, and J. Baugh Epigenetics, the epicenter of the hypoxic response Epigenetics 5 2010 293 296
98. P. Carrero, K. Okamoto, P. Coumailleau, S. O'Brien, H. Tanaka, and L. Poellinger Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha Mol Cell Biol 20 2000 402 415
99. J. Rossler, I. Stolze, and S. Frede et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site J Cell Biochem 93 2004 153 161
100. R.H. Wenger, I. Kvietikova, A. Rolfs, G. Camenisch, and M. Gassmann Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site Eur J Biochem 253 1998 771 777
101. G. Raspaglio, F. Filippetti, and S. Prislei et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3′ flanking region Gene 409 2008 100 108
102. U. Lendahl, K.L. Lee, H. Yang, and L. Poellinger Generating specificity and diversity in the transcriptional response to hypoxia Nat Rev Genet 10 2009 821 832
103. A.B. Johnson, N. Denko, and M.C. Barton Hypoxia induces a novel signature of chromatin modifications and global repression of transcription Mutat Res 640 2008 174 179
104. S. Shahrzad, K. Bertrand, K. Minhas, and B.L. Coomber Induction of DNA hypomethylation by tumor hypoxia Epigenetics 2 2007 119 125
105. C.N. Andreassen, and J. Alsner Genetic variants and normal tissue toxicity after radiotherapy: a systematic review Radiother Oncol 92 2009 299 309
106. D. De Ruysscher, D. Severin, and E. Barnes et al. First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II Radiother Oncol 97 2010 36 39
107. C.N. Andreassen Searching for genetic determinants of normal tissue radiosensitivity - are we on the right track? Radiother Oncol 97 2010 1 8
108. C.N. Andreassen, J. Alsner, and J. Overgaard Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it? Radiother Oncol 64 2002 131 140
109. J.H. Hendry Genomic instability: potential contributions to tumour and normal tissue response, and second tumours, after radiotherapy Radiother Oncol 59 2001 117 126
110. J.L. Guerra, D. Gomez, and Q. Wei et al. Association between single nucleotide polymorphisms of the transforming growth factor beta1 gene and the risk of severe radiation esophagitis in patients with lung cancer Radiother Oncol 105 2012 299 304
111. M. Baumann, T. Holscher, and A.C. Begg Towards genetic prediction of radiation responses: ESTRO's GENEPI project Radiother Oncol 69 2003 121 125
112. D.A. Antwih, K.M. Gabbara, W.D. Lancaster, D.M. Ruden, and S.P. Zielske Radiation-induced epigenetic DNA methylation modification of radiation-response pathways Epigenetics 8 2013 839 848
113. I. Pogribny, I. Koturbash, and V. Tryndyak et al. Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus Mol Cancer Res 3 2005 553 561
114. J. Raiche, R. Rodriguez-Juarez, I. Pogribny, and O. Kovalchuk Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice Biochem Biophys Res Commun 325 2004 39 47
115. I. Koturbash, F. Zemp, B. Kolb, and O. Kovalchuk Sex-specific radiation-induced microRNAome responses in the hippocampus, cerebellum and frontal cortex in a mouse model Mutat Res 722 2011 114 118
116. I. Koturbash, I. Pogribny, and O. Kovalchuk Stable loss of global DNA methylation in the radiation-target tissue - a possible mechanism contributing to radiation carcinogenesis? Biochem Biophys Res Commun 337 2005 526 533
117. I. Koturbash, A. Boyko, and R. Rodriguez-Juarez et al. Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo Carcinogenesis 28 2007 1831 1838
118. Y. Ilnytskyy, I. Koturbash, and O. Kovalchuk Radiation-induced bystander effects in vivo are epigenetically regulated in a tissue-specific manner Environ Mol Mutagen 50 2009 105 113
119. J. Loree, I. Koturbash, K. Kutanzi, M. Baker, I. Pogribny, and O. Kovalchuk Radiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesis Int J Radiat Biol 82 2006 805 815
120. C. Kuhmann, D. Weichenhan, M. Rehli, C. Plass, P. Schmezer, and O. Popanda DNA methylation changes in cells regrowing after fractioned ionizing radiation Radiother Oncol 101 2011 116 121
121. O. Kovalchuk, P. Burke, J. Besplug, M. Slovack, J. Filkowski, and I. Pogribny Methylation changes in muscle and liver tissues of male and female mice exposed to acute and chronic low-dose X-ray-irradiation Mutat Res 548 2004 75 84
122. K.L. Bennett, W. Lee, and E. Lamarre et al. HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas Gene Chromosome Cancer 49 2010 319 326
123. K. Ogawa, Y. Yoshioka, F. Isohashi, Y. Seo, K. Yoshida, and H. Yamazaki Radiotherapy targeting cancer stem cells: current views and future perspectives Anticancer Res 33 2013 747 754
124. C.A. Armstrong, G.D. Jones, and R. Anderson et al. DNMTs are required for delayed genome instability caused by radiation Epigenetics 7 2012 892 902
125. I. Koturbash, M. Baker, and J. Loree et al. Epigenetic dysregulation underlies radiation-induced transgenerational genome instability in vivo Int J Radiat Oncol Biol Phys 66 2006 327 330
126. B. Zhu, X. Huang, J. Chen, Y. Lu, Y. Chen, and J. Zhao Methylation changes of H19 gene in sperms of X-irradiated mouse and maintenance in offspring Biochem Biophys Res Commun 340 2006 83 89
127. J.M. Wagner, B. Hackanson, M. Lubbert, and M. Jung Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin Epigenet 1 2010 117 136
128. S.H. Song, S.W. Han, and Y.J. Bang Epigenetic-based therapies in cancer: progress to date Drugs 71 2011 2391 2403
129. J.C. Purrucker, A. Fricke, M.F. Ong, C. Rube, C.E. Rube, and U. Mahlknecht HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA double-strand break repair capacity Oncol Rep 23 2010 263 269
130. H. De Schutter, and S. Nuyts Radiosensitizing potential of epigenetic anticancer drugs Anticancer Agent Med Chem 9 2009 99 108
131. T.C. Karagiannis, H. Kn, and A. El-Osta The epigenetic modifier, valproic acid, enhances radiation sensitivity Epigenetics 1 2006 131 137
132. K.N. Harikrishnan, T.C. Karagiannis, M.Z. Chow, and A. El-Osta Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments Cell Cycle 7 2008 468 476
133. B.G. Debeb, W. Xu, and H. Mok et al. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions Int J Radiat Oncol Biol Phys 76 2010 889 895
134. M.A. Khalil, J. Hrabeta, S. Cipro, M. Stiborova, A. Vicha, and T. Eckschlager Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors Neoplasma 59 2012 737 746
135. H.J. Kim, J.H. Kim, E.K. Chie, P. Da Young, I.A. Kim, and I.H. Kim DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity Radiat Oncol 7 2012 39
136. A. Munshi, J.F. Kurland, and T. Nishikawa et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity Clin Cancer Res 11 2005 4912 4922
137. A. Munshi, T. Tanaka, M.L. Hobbs, S.L. Tucker, V.M. Richon, and R.E. Meyn Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci Mol Cancer Ther 5 2006 1967 1974
138. K. Camphausen, W. Burgan, and M. Cerra et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275 Cancer Res 64 2004 316 321
139. J.H. Kim, J.H. Shin, and I.H. Kim Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor Int J Radiat Oncol Biol Phys 59 2004 1174 1180
140. Y. Zhang, M. Jung, and A. Dritschilo Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors Radiat Res 161 2004 667 674
141. T. Kuribayashi, M. Ohara, S. Sora, and N. Kubota Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation Int J Mol Med 25 2010 25 29
142. M. Shoji, I. Ninomiya, and I. Makino et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma Int J Oncol 40 2012 2140 2146
143. C.M. Arundel, A.S. Glicksman, and J.T. Leith Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB) Radiat Res 104 1985 443 448
144. C.A. Banuelos, J.P. Banath, S.H. MacPhail, J. Zhao, T. Reitsema, and P.L. Olive Radiosensitization by the histone deacetylase inhibitor PCI-24781 Clin Cancer Res 13 2007 6816 6826
145. I.A. Kim, M. No, and J.M. Lee et al. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6 Radiother Oncol 92 2009 125 132
146. Y.S. Lu, C.H. Chou, and K.Y. Tzen et al. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma Int J Radiat Oncol Biol Phys 83 2012 e181 e189
147. Y.L. Chung, M.Y. Lee, and N.N. Pui Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis Carcinogenesis 30 2009 1387 1397
148. Y.L. Chung, A.J. Wang, and L.F. Yao Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy Mol Cancer Ther 3 2004 317 325
149. A.C. Miller, S. Cohen, M. Stewart, R. Rivas, and P. Lison Radioprotection by the histone deacetylase inhibitor phenylbutyrate Radiat Environ Biophys 50 2011 585 596
150. D.M. Hellebrekers, A.W. van Griffioen, and M. Engeland Dual targeting of epigenetic therapy in cancer Biochim Biophys Acta 1775 2007 76 91
151. H. Qiu, M. Yashiro, O. Shinto, T. Matsuzaki, and K. Hirakawa DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells Cancer Sci 100 2009 181 188
152. H. De Schutter, M. Kimpe, S. Isebaert, and S. Nuyts A systematic assessment of radiation dose enhancement by 5-Aza-2′-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 73 2009 904 912
153. H. Dote, D. Cerna, and W.E. Burgan et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine Clin Cancer Res 11 2005 4571 4579
154. A.T. Chan, Q. Tao, and K.D. Robertson et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors J Clin Oncol 22 2004 1373 1381
155. H.J. Cho, S.Y. Kim, and K.H. Kim et al. The combination effect of sodium butyrate and 5-Aza-2′-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines World J Surg Oncol 7 2009 49
156. S.D. Gore, S. Baylin, and E. Sugar et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 2006 6361 6369
157. H.C. Tsai, H. Li, and L. Van Neste et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Cell 21 2012 430 446
158. H. Shen, and P.W. Laird In epigenetic therapy, less is more Cell Stem Cell 10 2012 353 354
159. C. Ward, S.P. Langdon, and P. Mullen et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer Cancer Treat Rev 39 2013 171 179
160. H. Shi, L. Chen, and H. Wang et al. Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes Biochem Biophys Res Commun 430 2013 827 832
161. J. Yu, J. Mi, Y. Wang, A. Wang, and X. Tian Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela Eur J Gynaecol Oncol 33 2012 285 290
162. A. Naldini, I. Filippi, E. Cini, M. Rodriquez, F. Carraro, and M. Taddei Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells Anticancer Agent Med Chem 12 2012 407 413
163. J.P. Ioannidis Why most published research findings are false PLoS Med 2 2005 e124
164. P.W. Laird Principles and challenges of genomewide DNA methylation analysis Nat Rev Genet 11 2010 191 203
165. C. Bock Epigenetic biomarker development Epigenomics 1 2009 99 110
166. G. Quon, S. Haider, A.G. Deshwar, A. Cui, P.C. Boutros, and Q. Morris Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction Genome Med 5 2013 29
167. M.H. Starmans, M. Pintilie, and T. John et al. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies Genome Med 4 2012 84
168. P.C. Boutros, M. Pintilie, and T. John et al. Re: gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102 2010 1677 1678 author reply 1678-1679
169. J. Subramanian, and R. Simon Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102 2010 464 474
170. I.J. van Vlodrop, H.E. Niessen, and S. Derks et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17 2011 4225 4231
171. R.A. Irizarry, C. Ladd-Acosta, and B. Wen et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores Nat Genet 41 2009 178 186
172. J. Frigola, J. Song, C. Stirzaker, R.A. Hinshelwood, M.A. Peinado, and S.J. Clark Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band Nat Genet 38 2006 540 549.